Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glenmark PharmaceuticalsNSE:GLENMARK +0.18%88 Return-on-Tangible-Equity is 15.06% as of Mar. 2026, which is 20% below its 10-year median of 18.85. GuruFocus rates NSE:GLENMARK with a GF Score™ of 88/100 and a GF Value™ of ₹1,985.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 900 Drug Manufacturers companies, Glenmark Pharmaceuticals ranks better than 75.11% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Glenmark Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was ₹12,057 Mil. Glenmark Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹80,059 Mil. Therefore, Glenmark Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 15.06%.
The historical rank and industry rank for Glenmark Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:GLENMARK'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -22.13 Med: 18.85 Max: 28.74
Current: 17.64
During the past 13 years, Glenmark Pharmaceuticals's highest Return-on-Tangible-Equity was 28.74%. The lowest was -22.13%. And the median was 18.85%.
NSE:GLENMARK's Return-on-Tangible-Equity is ranked better than 75.11% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs NSE:GLENMARK: 17.64
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Glenmark Pharmaceuticals Return-on-Tangible-Equity Related Terms
Glenmark Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Glenmark Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLENMARK vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glenmark Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Glenmark Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.06% mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Return-on-Tangible-Equity of 15.06% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Glenmark Pharmaceuticals and its competitors. This is 20% below median its historical median of 18.85. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #224 out of 900 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is Glenmark Pharmaceuticals' Return-on-Tangible-Equity too high?
Glenmark Pharmaceuticals' current Return-on-Tangible-Equity of 15.06% is 20% below median its 10-year median of 18.85. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. Glenmark Pharmaceuticals' value of 15.06% is 90% above this industry median. Based on the distribution chart, Glenmark Pharmaceuticals ranks #224 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Glenmark Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #224 out of 900 companies for Return-on-Tangible-Equity. This places Glenmark Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.93. Glenmark Pharmaceuticals' value of 15.06% is 90% above this benchmark. While the company's 10-year median is 18.85 vs. the industry median of 7.93, Glenmark Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glenmark Pharmaceuticals's current Return-on-Tangible-Equity of 15.06% is 90% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Glenmark Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current Return-on-Tangible-Equity is 15.06%, which is 20% below median its own 10-year median of 18.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,985.14, compared to a current price of ₹2,196.00 — trading 10.6% above its estimated fair value. The current Return-on-Tangible-Equity is 15.06%, which is 20% below median its 10-year median of 18.85 and 90% above the Drug Manufacturers industry median of 7.93. Glenmark Pharmaceuticals' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Return-on-Tangible-Equity is 15.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,196.00 is trading 10.6% above its estimated GF Value™ of ₹1,985.14.
GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for NSE:GLENMARK:
Return-on-Tangible-Equity: 15.06% (20% below median its 10-year median of 18.85)
GF Value™: ₹1,985.14 vs. price of ₹2,196.00 (10.6% above fair value)
Industry Position: 90% above the Drug Manufacturers median (#224 of 900)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
88GF Score
Get the complete analysis for NSE:GLENMARK
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
